Dr Nancy Joy Smith, LPC | |
235 Hughes Rd, Suite B, Madison, AL 35758-1142 | |
(256) 924-2101 | |
Not Available |
Full Name | Dr Nancy Joy Smith |
---|---|
Gender | Female |
Speciality | Counselor - Professional |
Location | 235 Hughes Rd, Madison, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1750327458 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Nancy Joy Smith, LPC 235 Hughes Rd, Suite B, Madison, AL 35758-1142 Ph: (256) 924-2101 | Dr Nancy Joy Smith, LPC 235 Hughes Rd, Suite B, Madison, AL 35758-1142 Ph: (256) 924-2101 |
News Archive
In an analysis published Thursday in the online edition of the journal Science, a team led by virologist Peter Palese of Mount Sinai School of Medicine in New York argue the mortality rate from H5N1 bird flu is under one percent, much lower than the WHO's estimated fatality rate of 59 percent, Reuters reports.
The study, published yesterday in the journal Proceedings of the National Academy of Sciences (PNAS), looked at how genes on sex-linked chromosomes are passed down generations and linked to fertility, using the specific example of the W chromosome in female chickens.
The age of the father at the time his children are born may influence their social development, suggests a study published in the May 2017 issue of the Journal of the American Academy of Child and Adolescent Psychiatry.
Elsevier, a world-leading publisher of scientific, medical and technical products and services, introduces Protein Viewer, a new, interactive feature on SciVerse ScienceDirect for the Journal of Molecular Biology (JMB). With Protein Viewer, readers of JMB now have the power to expand and rotate molecules within the actual article. SciVerse ScienceDirect merges features of the World Protein Database and Jmol, and embeds them into the article, making its use more convenient and user-friendly.
The National Institutes of Health (NIH) has awarded United Therapeutics Corporation a contract for up to $45 million over five years "to help develop a potential oral treatment for viruses like influenza and the mosquito-borne tropical fever dengue," the Associated Press/Washington Post reports.
› Verified 5 days ago